Dalainas Ilias, Moros Ioannis, Gerasimidis Thomas, Papadimitriou Dimitris, Saratzis Nikos, Gitas Christos G, Kiskinis Dimitrios, Lazaridis Jean
1st Surgical Department, Aristotle University, Thessaloniky, Greece.
Ann Vasc Surg. 2007 May;21(3):339-45. doi: 10.1016/j.avsg.2006.06.005. Epub 2007 Feb 23.
The aim of this prospective study was to compare the outcome of the Talent bifurcated endograft versus the Endofit aorto-uni-iliac endograft in the short-term and mid-term. Between March 2000 and December 2003, 86 patients were treated with the Talent bifurcated endograft (group A) and 21 with the Endofit aorto-uni-iliac endograft (group B) in the same institute by the same surgical team. All patients followed a prospective protocol of preoperative evaluation and postoperative follow-up. We compared groups A and B in terms of perioperative mortality and morbidity, mid-term endoleak rate, mid-term success rate, and mid-term survival. The perioperative mortality for group A was 1.63%, while that for group B was 0% (P = 0.62). The endoleak rate for group A was 4.65%, and that for group B was 14.29% (P = 0.135). The mid-term success rate was 96.5% for group A and 100% for group B (P = 0.386). There was no significant difference in outcome between the patients treated with the Talent and those treated with the Endofit endoprosthesis. Treating abdominal aortic aneurysms with aorto-uni-iliac endoprosthesis is as safe and effective as treating them with bifurcated endografts.
这项前瞻性研究的目的是比较Talent分叉型腔内移植物与Endofit主动脉单髂动脉腔内移植物在短期和中期的治疗效果。在2000年3月至2003年12月期间，同一机构的同一手术团队对86例患者使用Talent分叉型腔内移植物进行治疗（A组），对21例患者使用Endofit主动脉单髂动脉腔内移植物进行治疗（B组）。所有患者均遵循术前评估和术后随访的前瞻性方案。我们比较了A组和B组在围手术期死亡率和发病率、中期内漏率、中期成功率和中期生存率方面的情况。A组的围手术期死亡率为1.63%，而B组为0%（P = 0.62）。A组的内漏率为4.65%，B组为14.29%（P = 0.135）。A组的中期成功率为96.5%，B组为100%（P = 0.386）。使用Talent腔内移植物治疗的患者与使用Endofit腔内假体治疗的患者在治疗效果上没有显著差异。用主动脉单髂动脉腔内假体治疗腹主动脉瘤与用分叉型腔内移植物治疗一样安全有效。
